Immunotherapy drug improves outcomes for some children with relapsed leukemia

For children and young adults with certain relapsed B-cell acute lymphoblastic leukemia (B-ALL), the immunotherapy drug blinatumomab is superior to standard chemotherapy, an NCI-sponsored Children’s Oncology Group trial shows.

from NCI News Releases https://ift.tt/2E2GwVV